SyntheticMR announces estimated net sales for the first quarter 2022 due to delays in customers' purchasing processes
There is a great interest in and demand for SyntheticMR's products in all priority markets. However, a number of purchasing processes with significant order values are delayed at the customer level, which affects the outcome in the quarter. The processes are still ongoing and the experience so far is that the restrictions are temporary and have no long-term impact.
Net sales for the first quarter 2022 are estimated to amount to approximately SEK 10 million (14.7). The figures are preliminary and unaudited. The full interim report for the first quarter will be published on May 10, 2022, as previously announced.
“As communicated earlier, our business sometimes have large fluctuations over the quarters. It is important to point out, however, that the response from the market for our offerings after the previous record quarter is unabated strong. My solid belief in the potential for the current and coming years is intact”, says Ulrik Harrysson, CEO, SyntheticMR.
This disclosure contains information that SyntheticMR AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 05-04-2022 18:26 CET.
For additional information, please contact Ulrik Harrysson, CEO, SyntheticMR AB, +46 70 529 29 87 ulrik.harrysson@syntheticmr.com.
SyntheticMR AB develops and markets innovative software solutions for Magnetic Resonance Imaging (MRI). SyntheticMR AB has developed SyMRI®, delivering multiple, adjustable contrast images and quantitative data from a single 5-minute scan. The SyMRI product is available in different packages. SyMRI NEURO delivers multiple contrast images, tissue segmentations and quantitative data on the brain. SyMRI KNEE and SyMRI SPINE provides multiple contrast images and quantitative data for knee and spine anatomies. SyMRI NEURO is CE-marked and FDA 510(k) cleared and SyMRI KNEE and SyMRI SPINE is CE-marked. SyMRI is a registered trademark in Europe and the USA. SyntheticMR is listed on the Spotlight Stock Market Exchange in Stockholm, Sweden. For more information, visit www.syntheticmr.com.